LC
RVMD icon

Lunate Capital’s Revolution Medicines RVMD Stock Holding History

Lunate Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-549,050
Closed -$53.4M – 11
2026
Q1 		$53.4M Sell
549,050
-1,647,150
-75% -$166M 44.36% 1
2025
Q4 		$175M Hold
2,196,200
– – 66.2% 1
2025
Q3 		$103M Hold
2,196,200
– – 46.47% 1
2025
Q2 		$80.8M Hold
2,196,200
– – 45.37% 1
2025
Q1 		$77.7M Buy
+2,196,200
New +$89.1M 45.36% 1

Other funds holding RVMD

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Lunate Capital's RVMD Position: Q2 2026 in Review

Lunate Capital sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 549,050 shares — an estimated $53.4M sold.

Lunate Capital first reported a position in RVMD in Q1 2025 and held it in 5 quarters. The position peaked at $175M in Q4 2025. 186 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Lunate Capital reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Lunate Capital sold 549,050 Revolution Medicines shares in Q2 2026, an estimated $53.4M.
  • Lunate Capital first reported a position in Revolution Medicines in Q1 2025 and held it in 5 quarters.
  • Lunate Capital's Revolution Medicines position peaked at $175M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Lunate Capital's 13F filing for Q2 2026, filed 23 Jul 2026.